
Nova Biomedical Launches Allegro CRP Test in CE Regulated Countries



[Nova Biomedical](#) announces the addition of C-reactive protein (CRP) testing to its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter provides 11 clinically important tests to help physicians make therapeutic decisions and adjustments during the patient visit. The Allegro analyzer and this new CRP test are available in CE regulated countries. Allegro will be submitted to the U.S. FDA for CLIA waived use.

CRP is a protein made by the liver and is sent into the bloodstream in response to inflammation. Allegro's CRP test measures the amount of CRP in whole blood to detect inflammation due to acute conditions such as infection or to monitor chronic conditions including cardiovascular disease and autoimmune disease. CRP is just one of 11 tests for the Allegro platform, including glycated hemoglobin (HbA1c), Total Cholesterol, HDL Cholesterol, LDL Cholesterol Triglyceride, Glucose, Blood Creatinine, PT/INR, Urine Albumin and Urine Creatinine.

Allegro tests use capillary fingerstick samples for all tests, eliminating the need for venipuncture or a trained phlebotomist. All tests use disposable test cartridges or strips. Allegro's quick six to nine-minute cartridge test times, less than 30 second test strip times, and ability to measure two cartridges simultaneously provide rapid results immediately to the physician during the patient visit. Having immediate results during the patient visit simplifies workflow and reduces clinic follow-up calls, letters, and patient re-visits, and improves patient compliance with care plans.

Published on : Mon, 5 Oct 2020